Board


Our highly-experienced Board has a track record of developing products in the life science and healthcare industry and of successfully selling Australian companies to US-based acquirers.


Paul MacLeman

CHAIRMAN

Paul has wide ranging, hands-on experience across the biotechnology sector, encompassing technical, commercial and financial areas. With a career-spanning veterinary practice, the pharmaceutical/biotechnology and investment banking sectors, Paul has experience in capital raising, business development, research management, technology commercialisation, staff development, and sales and marketing. He has also founded life sciences startups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Paul is currently CEO of ASX-listed pharmaceutical manufacturing company IDT Australia Ltd (ASX:IDT).


Sam Cobb

MANAGING DIRECTOR & CEO

Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies. Prior to AdAlta, Sam was the Business Development Director at the Co-operative Research Centre for Diagnostics. Sam has also worked for the biotech start up companies Sensologix Inc and Nephrogenix Pty Ltd and at the University of Queensland’s technology commercialisation companies, Uniquest Pty Ltd and IMBcom Pty Ltd. Sam has a Bachelor of Science, a Masters of Intellectual Property Law and has completed the Australian Institute of Company Directors course.


James Williams PhD

NON-EXECUTIVE DIRECTOR

James is a co-founder and Investment Director of Yuuwa Capital LP, a venture capital firm based in Western Australia. Prior to Yuuwa Capital, he was Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which secured regulatory approvals under his leadership. He conceived, co-founded and is a former CTO and Director of iCeutica, Inc., a clinical stage nano drug reformulation company. iCeutica was acquired by Philadelphia-based Iroko Pharmaceuticals in 2011, achieving a ten-fold uplift on the valuation of the company from its original capital raising value. Iroko received FDA approval for the first three iCeutica formulations between 2013 and 2015. James is the Executive Chariman of ASX-listed clinical stage drug discovery and development company Dimerix Ltd (ASX:DXB) and Director of Yuuwa investee companies PolyActiva Pty Ltd and Nexgen Plants Pty Ltd. He is also a Director of Linear Clinical Research Ltd, a specialist early phase clinical trial unit and a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund.


Liddy McCall

NON-EXECUTIVE DIRECTOR

Liddy is a co-founder and Investment Director of Yuuwa Capital LP. Liddy is also a Director of Yuuwa investee companies Gordiantec Pty Ltd and iCetana Pty Ltd. Her experience includes drug development and medical device projects. She was a co-founder and director of iCeutica Inc. iCeutica was acquired by Philadelphia-based Iroko Pharmaceuticals in 2011. Iroko received FDA approval for the first three iCeutica formulations between 2013 and 2015. Liddy was co-founder and Director of Tessitura Pty Ltd, a consulting company providing services to the biotechnology industry. Previously, Liddy was an Associate Director in the Corporate Advisory Group of Macquarie Bank and prior to that worked as a lawyer with a leading Australian law firm.


Robert Peach PhD

NON-EXECUTIVE DIRECTOR

Dr Peach has over 25 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry.  In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising $59M in venture capital and $800M in an IPO and three subsequent follow-on offerings.  In August 2015 Receptos was acquired by Celgene for $7.8B.  Robert held senior executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol-Myers Squibb, supporting in-licensing, acquisition and venture investments.  His extensive drug discovery and development experience in autoimmune and inflammatory diseases, and cancer has resulted in multiple drugs entering clinical trials and 3 registered drugs.  He currently serves on the Board of Directors of Innate Immunotherapeutics and Avalia Immunotherapies and is a consultant for several other biotechnology companies. Robert is the co-author of 70 scientific publications and book chapters, and 17 patents.  He was educated at the University of Canterbury and the University of Otago, New Zealand.


John Chiplin PhD

NON-EXECUTIVE DIRECTOR

John has significant international experience in the life science and technology industries, from both an operational and investment perspective. Recent transactions in which John has been instrumental include Benitec BioPharma (US IPO), Medistem (acquired by Intrexon Corporation for US$26 million), former CEO of ASX-listed Arana Therapeutics (acquired by Cephalon Inc. for US$200 million), and Domantis (acquired by GSK for £230 million). Immediately prior to running Arana, John was head of the ITI Life Sciences investment fund in the UK, negotiating significant funding with Government Ministers. His own investment company, Newstar Ventures Ltd., has funded more than a dozen early stage companies in the past ten years. John’s Pharmacy and Doctoral degrees are from the University of Nottingham, UK. He currently serves on the boards of Batu Biologics, Benitec BioPharma (NASDAQ:BNTC), The Coma Research Institute, Cynata Therapeutics (ASX:CYN), Prophecy Inc, Scancell Holdings plc (LSE:SCLP), and ScienceMedia Inc.


Cameron Jones

COMPANY SECRETARY

Cameron Jones is a Chartered Accountant and holds a Certificate in Governance (Practice) from the Governance Institute of Australia and assumes responsibility for Australian Securities and Investments (ASIC) reporting, ASX compliance and reporting, planning and execution of annual reporting and shareholder meetings as well as Chief Financial Officer of AdAlta. Cameron is also a Director of Bio101Group Pty Ltd, a wholly owned subsidiary of Biotech Capital Limited and has previously worked at Pitcher Partners.